Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease (SPRINT)

Teva Pharmaceuticals

Status: Completed

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Treatments: Drug: Marketed antagonists

Study type: Observational

Funder types: Industry

Identifiers

NCT02419872

BFS-AS-40087

Details and patient eligibility

About

The study is to evaluate the percentage of patients with asthma or COPD achieving disease control

Full description

There are no treatment groups or interventions to which the patients can be randomly assigned. Data will be collected in a routine setting on a single occasion during an otherwise normal visit at the physician's office or clinic. Participating physicians will not perform any medical procedures that are outside of their normal daily clinical practice. All treatment decisions are at the sole discretion of the participating physicians and reflect their current standard of care

Enrollment: 1,743 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient ≥ 18 years of age who has been diagnosed with persistent asthma or patient ≥ 40 years of age and/or (ex)-smoker with more than 10 pack years of smoking who has been diagnosed with COPD
• Treatment with a stable dose (no change in dose or change by less than 50% in the last 3 months) of a Inhaled corticosteroid (ICS), Long-acting beta2-agonists (LABA), Fixed dose combination (FDC) administered twice daily by Dry powder inhaler (DPI) for 3 months prior to enrollment in accordance with its approved indication
• Patient is willing and able to provide written informed consent;
• Patient agrees to participate in the study and to disclose any medical events to the treating physician;
• Patient is able to complete the questionnaires.

Exclusion criteria

• Current enrolment or planned enrolment in an interventional study (patients are allowed to participate in other observational or case-control studies).

Trial design

1,743 participants in 1 patient group

Patient Participants

Description:

Patients are confirmed to have either Persistent Asthma or COPD

Treatment:

Drug: Marketed antagonists